Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies

Journal of Mass Spectrometry

Volumn 50, Issue 2, 2015, Pages 285-297

  Beck, Alain ^a   Debaene, François ^b,c   Diemer, Hélène ^b,c   Wagner Rousset, Elsa ^a   Colas, Olivier ^a   Dorsselaer, Alain Van ^b,c   Cianférani, Sarah ^b,c  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c CNRS   (France)

Author keywords

antibody; biobetter; biosimilar; cetuximab; critical quality attribute; glycosylation; mass spectrometry; trastuzumab

Indexed keywords

CAPILLARY ELECTROPHORESIS; CHROMATOGRAPHY; CUTTING TOOLS; DISSOCIATION; ELECTROPHORESIS; GLYCOSYLATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MONOCLONAL ANTIBODIES; SPECTROMETRY;

BIOBETTER; BIOSIMILAR; CETUXIMAB; CRITICAL QUALITY; TRASTUZUMAB;

ANTIBODIES;

ANTIBODY; BIOBETTER ANTIBODY; BIOSIMILAR AGENT; CD16 ANTIGEN; CETUXIMAB; GLYCOPEPTIDE; ORIGINATOR ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; CAPILLARY ZONE ELECTROPHORESIS; CELL MEDIATED CYTOTOXICITY; DEAMINATION; DEGLYCOSYLATION; DEUTERIUM HYDROGEN EXCHANGE; DRUG INDUSTRY; ELECTRON TRANSFER DISSOCIATION; ELECTRON TRANSPORT; GLYCOSYLATION; ION MOBILITY SPECTROMETRY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN PROCESSING; TANDEM MASS SPECTROMETRY; TOP DOWN SEQUENCING; AMINO ACID SEQUENCE; ANIMAL; CAPILLARY ELECTROPHORESIS; CHEMISTRY; HUMAN; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; CETUXIMAB; ELECTROPHORESIS, CAPILLARY; GLYCOSYLATION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; TANDEM MASS SPECTROMETRY; TRASTUZUMAB;

EID: 84925363068     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.3554     Document Type: Article

References (53)

1. A. Beck,. Biosimilar, biobetter and next generation therapeutic antibodies. MAbs 2011, 3, 107.
2. A. Beck, S. Sanglier-Cianferani, A. Van Dorsselaer,. Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry. Anal.Chem. 2012, 84, 4637.
3. C.K. Schneider, C. Vleminckx, I. Gravanis, F. Ehmann, J.H. Trouvin, M. Weise, S. Thirstrup,. Setting the stage for biosimilar monoclonal antibodies. Nat.Biotechnol. 2012, 30, 1179.
4. J. M. Reichert, A. Beck, H. Iyer,. European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London UK, MAbs 2009, 1, 394.
5. A. Beck, J. M. Reichert,. Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 2013, 5, 621.
6. A. Beck, J. M. Reichert,. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 2011, 3, 415.
7. A. Beck, T. Wurch, C. Bailly, N. Corvaia,. Strategies and challenges for the next generation of therapeutic antibodies. Nat.Rev.Immunol. 2010, 10, 345.
8. J. M. Reichert, A. Beck, A. A. Lugovskoy, T. Wurch, S. Coats, R. J. Brezski,. 9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland. MAbs 2014, 6, 309.
9. A. Mullard,. Hearing shines spotlight on biosimilar controversies. Nat.Rev.Drug Discov. 2010, 9, 905.
10. H. Xie, A. Chakraborty, J. Ahn, Y. Q. Yu, D. P. Dakshinamoorthy, M. Gilar, W. Chen, S. J. Skilton, J. R. Mazzeo,. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2010, 2, 379.
11. C. Li, A.Rossomando, S. L. Wu, B. L. Karger,. Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches. MAbs 2013, 5, 565.
12. Q. Tan, Q. Guo, C. Fang, C. Wang, B. Li, H. Wang, J. Li, Y. Guo,. Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products. MAbs 2012, 4, 761.
13. A. Beck, H. Diemer, D. Ayoub, F. Debaene, E. Wagner-Rousset, C. Carapito, A. Van Dorsselaer, S. Sanglier-Cianférani,. Analytical characterization of biosimilar antibodies and Fc-fusion proteins. TrAC Trends in Analytical Chemistry 2013, 48, 81.
14. D. Ayoub, W. Jabs, A. Resemann, W. Evers, C. Evans, L. Main, C. Baessmann, E. Wagner-Rousset, D. Suckau, A. Beck,. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs 2013, 5, 699.
15. A. Beck, E. Wagner-Rousset, D. Ayoub, A. Van Dorsselaer, S. Sanglier-Cianferani,. Characterization of therapeutic antibodies and related products. Anal.Chem. 2013, 85, 715.
16. R. J. Harris, B. Kabakoff, F. D. Macchi, F. J. Shen, M. Kwong, J. D. Andya, S. J. Shire, N. Bjork, K. Totpal, A. B. Chen,. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J.Chomatogr.B Biomed.Sci.Appl. 2001, 752, 233.
17. C. W. Damen, W. Chen, A. B. Chakraborty, M. van Oosterhout, J. R. Mazzeo, J. C. Gebler, J. H. Schellens, H. Rosing, J. H. Beijnen,. Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab. J.Am.Soc.Mass Spectrom. 2009, 20, 2021.
18. J. Qian, T. Liu, L. Yang, A. Daus, R. Crowley, Q. Zhou,. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal.Biochem. 2007, 364, 8.
19. S. Sundaram, A. Matathia, J. Qian, J. Zhang, M. C. Hsieh, T. Liu, R. Crowley, B. Parekh, Q. Zhou,. An innovative approach for the characterization of the isoforms of a monoclonal antibody product. MAbs 2011, 3, 505.
20. A. Wiegandt, B. Meyer,. Unambiguous characterization of N-glycans of monoclonal antibody cetuximab by integration of LC-MS/MS and (1)H NMR spectroscopy. Anal.Chem. 2014, %20; 86, 4807.
21. C. H. Chung, B. Mirakhur, E. Chan, Q. T. Le, J. Berlin, M. Morse, B. A. Murphy, S. M. Satinover, J. Hosen, D. Mauro, R. J. Slebos, Q. Zhou, D. Gold, T. Hatley, D. J. Hicklin, T. A. Platts-Mills,. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N.Engl.J.Med. 2008, 358, 1109.
22. A. Beck, O. Cochet, T. Wurch,. GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins. Expert Op.Drug Discov. 2010, 5, 95.
23. C. Wang, X. He, B. Zhou, J. Li, B. Li, W. Qian, S. Hou, H. Wang, Y. Shi, Y. Guo,. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors. MAbs 2011, 3, 67.
24. R. Jefferis, M. P. Lefranc,. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009, 1, 332.
25. A. Beck, T. Wurch, N. Corvaïa,. Editorial: Therapeutic Antibodies and derivatives: from the bench to the clinic. Curr.Pharm.Biotechnol. 2008, 9, 421.
26. E. Wagner-Rousset, A. Bednarczyk, M. C. Bussat, O. Colas, N. Corvaïa, C. Schaeffer, M. Van Dorsselaer, A. Beck,. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J.Chromatogr.B Analyt.Technol.Biomed. Life Sci. 2008, 872, 23.
27. S. Rosati, Y. Yang, A. Barendregt, A. J. Heck,. Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nat.Protoc. 2014, 9, 967.
28. A. Beck, M. C. Bussat, N. Zorn, V. Robillard, C. Klinguer-Hamour, S. Chenu, L. Goetsch, N. Corvaía, A. Van Dorsselaer, J. F. Haeuw,. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J.Chromatogr.B Analyt.Technol.Biomed.Life Sci. 2005, 819, 203.
29. W. Xu, Y. Peng, F. Wang, B. Paporello, D. Richardson, H. Liu,. Method to convert N-terminal glutamine to pyroglutamate for characterization of recombinant monoclonal antibodies. Anal.Biochem. 2013, 436, 10.
30. R. Gahoual, A. Burr, J. M. Busnel, L. Kuhn, P. Hammann, A. Beck, Y. N. François, E. Leize-Wagner,. Rapid and multi-level characterization of trastuzumab using sheathless capillary electrophoresis-tandem mass spectrometry. MAbs 2013, 5, 479.
31. H. Wei, J. Mo, L. Tao, R. J. Russell, A. A. Tymiak, G. Chen, R. E. Iacob, J. R. Engen,. Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications. Drug Discov.Today. 2014, 19, 95.
32. R. E. Iacob, G. M. Bou-Assaf, L. Makowski, J. R. Engen, S. A. Berkowitz, D. Houde,. Investigating monoclonal antibody aggregation using a combination of H/DX-MS and other biophysical measurements. J.Pharm.Sci. 2013, 102, 4315.
33. M. C. Janin-Bussat, L. Tonini, C. Huillet, O. Colas, C. Klinguer-Hamour, N. Corvaïa, A. Beck,. Cetuximab Fab and Fc N-Glycan Fast Characterization Using IdeS Digestion and Liquid Chromatography Coupled to Electrospray Ionization Mass Spectrometry. In: Glycosylation Engineering of Biopharmaceuticals, A. Beck, (Ed) Springer: New York, 2013
34. C. Atmanene, E. Wagner-Rousset, M. Malissard, B. Chol, A. Robert, N. Corvaïa, M. Van Dorsselaer, A. Beck, S. Sanglier-Cianférani,. Extending mass spectrometry contribution to therapeutic monoclonal antibody lead optimization: characterization of immune complexes using noncovalent ESI-MS. Anal.Chem. 2009, 81, 6364.
35. B. Kukrer, V. Filipe, E. van Duijn, P. T. Kasper, R. J. Vreeken, A. J. Heck, W. Jiskoot,. Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography. Pharm.Res. 2010, 27, 2197.
36. S. Fekete, A. Beck, J. L. Veuthey, D. Guillarme,. Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J.Pharm.Biomed.Anal. 2014, %19. pii: S0731-7085, 10.
37. F. Debaene, E. Wagner-Rousset, O. Colas, D. Ayoub, N. Corvaïa, A. Van Dorsselaer, A. Beck, S. Cianférani,. Time resolved native ion-mobility mass spectrometry to monitor dynamics of IgG4 Fab arm exchange and « bispecific» monoclonal antibody formation. Anal.Chem. 2013, 85, 9785.
38. D. Bagal, J. F. Valliere-Douglass, A. Balland, P. D. Schnier,. Resolving disulfide structural isoforms of IgG2 monoclonal antibodies by ion mobility mass spectrometry. Anal.Chem. 2010, 82, 6751.
39. K. J. Pacholarz, M. Porrini, R. A. Garlish, R. J. Burnley, R. J. Taylor, A. J. Henry, P. E. Barran,. Dynamics of intact immunoglobulin g explored by drift-tube ion-mobility mass spectrometry and molecular modeling. Angew.Chem.Int.Ed Engl. 2014, 53, 7765.
40. Y. O. Tsybin,. From high- to super-resolution mass spectrometry. Chimia (Aarau.). 2014, 68, 168.
41. L. Fornelli, D. Ayoub, K. Aizikov, A. Beck, Y. O. Tsybin,. Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry. Anal.Chem. 2014, 86, 3005.
42. J. Vlasak, M. C. Bussat, S. Wang, E. Wagner-Rousset, M. Schaefer, C. Klinguer-Hamour, M. Kirchmeie, M. Corvaïa, R. Ionescu, A. Beck,. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal.Biochem. 2009, 392, 145.
43. S. Fekete, A. Beck, J. Fekete, D. Guillarme,. Method development for the separation of mAbs charge variants in cation exchange chromatography, part I: Salt gradient approach. J. Pharm. Biomed. Anal. In press.
44. S. Fekete, A. Beck, J. Fekete, D. Guillarme,. Method development for the separation of mAbs charge variants in cation exchange chromatography, part II: pH gradient approach. J. Pharm. Biomed. Anal. In press.
45. R. Jefferis,. Glycosylation as a strategy to improve antibody-based therapeutics. Nature Rev.Drug Discov. 2009, 8, 226.
46. R. Gahoual, J. M. Busnel, A. Beck, Y. N. Francois, E. Leize-Wagner,. Full protein antibody primary structure and micro-variant assesment in a single injection using transient isotachophoresis and sheathless capillary electrophoresis-tandem mass spectrometry. Anal. Chem. In press.
47. R. Gahoual, J.-M. Busnel, J. Chicher, L. Kuhn, P. Hammann, A. Beck, N. Y. François, E. Leize-Wagner,. Monolconal antibodies biosimilarity assesment using transient isotachophoresis pre-concentration-capillary zone electrophoresis-tandem mass spectrometry. MAbs. In press.
48. M. Biacchi, R. Bhajun, N. Saïd, A. Beck, Y. N. François, E. Leize-Wagner,. Analysis of monoclonal antibody by a novel CE-UV/MALDI-MS interface isotachophoresis preconcentration-capillay zone electrophoresis-tandem mass spectrometry. Electrophoresis. In press.
49. A. Zhang, P. Hu, P. MacGregor, Y. Xue, H. Fan, P. Suchecki, L. Olszewski, A. Liu,. Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and structural modeling. Anal.Chem. 2014, 86, 3468.
50. D. Houde, S. A. Berkowitz, J. R. Engen,. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J.Pharm.Sci. 2011, 100, 2071.
51. L. Tang, S. Sundaram, J. Zhang, P. Carlson, A. Matathia, B. Parekh, Q. Zhou, M. C. Hsieh,. Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry. MAbs 2013, 5, 114.
52. J. Visser, I. Feuerstein, T. Stangler, T. Schmiederer, C. Fritsch, M. Schiestl,. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013, 27, 495.
53. K. Smet, G. Reichmann, J. Willem Lann, C. K. Schneider, L. van Aerts,. Biosimilars entering the clinic without animal studies: A paradigm shift in the EU. MAbs 2014, 6, 12.